Question 1

Am I eligible for this trial based on my cancer's genetic profile?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Isunakinra Alone and in Combination With Pembrolizumab in Patients With Colorectal Cancer (MSS) clinical trial (NCT06634875). Contact the study team or your healthcare provider for specific answers.

Question 2

What are the potential side effects of isunakinra and pembrolizumab?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Isunakinra Alone and in Combination With Pembrolizumab in Patients With Colorectal Cancer (MSS) clinical trial (NCT06634875). Contact the study team or your healthcare provider for specific answers.

Question 3

How does this treatment compare to other options available for my condition?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Isunakinra Alone and in Combination With Pembrolizumab in Patients With Colorectal Cancer (MSS) clinical trial (NCT06634875). Contact the study team or your healthcare provider for specific answers.

Question 4

What will my treatment schedule look like if I participate?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Isunakinra Alone and in Combination With Pembrolizumab in Patients With Colorectal Cancer (MSS) clinical trial (NCT06634875). Contact the study team or your healthcare provider for specific answers.

Question 5

Are there any risks or considerations I should be aware of before joining this trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Isunakinra Alone and in Combination With Pembrolizumab in Patients With Colorectal Cancer (MSS) clinical trial (NCT06634875). Contact the study team or your healthcare provider for specific answers.

Question 6

What support will be available for me during the trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Isunakinra Alone and in Combination With Pembrolizumab in Patients With Colorectal Cancer (MSS) clinical trial (NCT06634875). Contact the study team or your healthcare provider for specific answers.

What this study is about